14 July 2017 - The government’s Accelerated Access Review was supposed to herald a new age of innovation in the NHS, cutting drug development times and encouraging the use of novel medicines and treatments.

But a new set of policies from the government has fallen short of the ambitions of former life sciences minister, George Freeman, who began the Accelerated Access Review back in 2014.

The government has admitted it has delayed many of the policies that pharma hoped would encourage the NHS to use more novel drugs, and stimulate the life sciences industry.

Read Pharmaphorum article